-
Why Plug Power's Lead In Fuel Cell, Hydrogen Space Could Create 'Outsized Winner'
Wednesday, January 13, 2021 - 11:05am | 408Read More...Plug Power Inc (NASDAQ: PLUG) shares are primed for further gains, according to H.C. Wainwright, which issued a new Street-high price target for the fuel cell manufacturer. The Plug Power Analyst: Analyst Amit Dayal maintained a Buy rating on Plug Power and increased the price target from $60...
-
Novavax Analysts Confident As Coronavirus Vaccine Candidate Heads To Phase 3 Study
Friday, September 25, 2020 - 9:35am | 563Read More...Novavax, Inc. (NASDAQ: NVAX) announced late Thursday the initiation of a late-stage study of its investigational coronavirus vaccine, NVX-CoV2373, in the U.K. The Novavax Analysts: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax with a $290 price target...
-
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Monday, September 14, 2020 - 11:47am | 901Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...
-
Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization
Wednesday, September 9, 2020 - 10:09am | 324Read More...Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to manufacture Inovio's DNA COVID-19 vaccine. The Inovio Analyst: H.C. Wainwright analyst Raghuram Selvaraju...
-
After Mixed Q2 Report, Novavax Analyst Details Possible Coronavirus Vaccine Catalysts
Tuesday, August 11, 2020 - 11:01am | 427Read More...Novavax, Inc. (NASDAQ: NVAX) released better-than-expected bottom-line results for the second quarter Monday, although revenue trailed estimates. An analyst at H.C. Wainwright said they're focusing on the key milestone events for the company's coronavirus vaccine candidate after the...
-
Applied DNA Analyst Says Coronavirus Testing, Vaccine Work Could Drive Major Upside
Thursday, July 2, 2020 - 12:08pm | 425Read More...Shares of Applied DNA Sciences Inc (NASDAQ: APDN), which is in the race to develop a vaccine for the novel coronavirus, offer an attractive buying opportunity, according to H.C. Wainwright. The Applied DNA Analyst: Yi Chen initiated coverage of Applied DNA shares with a Buy rating and $18...
-
Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
Monday, June 29, 2020 - 1:17pm | 443Read More...Novavax, Inc. (NASDAQ: NVAX) shares are on a dream run this year amid catalysts including its COVID-19 vaccine program. The Novavax Analyst: Vernon Bernardino reiterated a top pick Buy rating on Novavax and raised the price target from $50 to $101. The Novavax Thesis: Novavax...
-
Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally
Monday, June 29, 2020 - 9:37am | 496Read More...Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%. Much of the upside stemmed from a $71-million DoD contract award for its COVID-19 vaccine delivery device. The...
-
Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit
Thursday, June 11, 2020 - 10:31am | 305Read More...Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19. What Happened: Sorrento said it has filed for an Emergency Use Authorization for its in vitro diagnostic test kit...
-
Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline
Thursday, May 21, 2020 - 1:52pm | 543Read More...A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus...
-
Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options
Monday, May 18, 2020 - 1:36pm | 476Read More...Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection. The Sorrento Analyst H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $...
-
5 ASCO Abstracts Moving Biopharma Stocks
Thursday, May 14, 2020 - 2:17pm | 851Read More...The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...
-
Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report
Tuesday, May 12, 2020 - 1:49pm | 550Read More...Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate. The Inovio Analysts Stifel analyst Stephen Wiley maintained a Buy rating and $19 price target for Inovio...
-
Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development
Tuesday, May 12, 2020 - 1:08pm | 754Read More...Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...
-
Bidding War Sends Tetraphase Shares Soaring
Thursday, May 7, 2020 - 11:55am | 679Read More...Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged. Two-way Race The Watertown, Massachusetts-based company, which has a...
